Literature DB >> 22788384

Stroke due to atrial fibrillation in a population-based stroke registry (Ludwigshafen Stroke Study) CHADS(2) , CHA(2) DS(2) -VASc score, underuse of oral anticoagulation, and implications for preventive measures.

F Palm1, T Kleemann, M Dos Santos, C Urbanek, F Buggle, A Safer, M G Hennerici, H Becher, R Zahn, A J Grau.   

Abstract

BACKGROUND AND
PURPOSE: Atrial fibrillation (AF) is amongst the most important etiologies of ischaemic stroke. In a population-based stroke registry, we tested the hypothesis of low adherence to current guidelines as a main cause of high rates of AF-associated stroke.
METHODS: Within the Ludwigshafen Stroke Study (LuSSt), a prospective ongoing population-based stroke register, we analyzed all patients with a first-ever ischaemic stroke (FEIS) owing to AF in 2006 and 2007. We determined whether AF was diagnosed before stroke and assessed pre-stroke CHADS(2) and CHA(2) DS(2) -VASc scores.
RESULTS: In total, 187 of 626 patients with FEIS suffered from cardioembolic stroke owing to AF, which was newly diagnosed in 57 (31%) patients. Retrospective pre-stroke risk stratification according to CHADS(2) score indicated low/intermediate risk in 34 patients (18%) and high risk (CHADS(2)  ≥ 2) in 153 patients (82%). Application of CHA(2) DS(2) -VASc score reduced number of patients at low/intermediate risk (CHA(2) DS(2) -VASc score 0-1) to five patients (2.7%). In patients with a CHADS(2) score ≥ 2 and known AF (n = 106) before stroke, 38 (36%) were on treatment with vitamin K antagonists on admission whilst only in 16 patients (15%) treatment was in therapeutic range.
CONCLUSIONS: Our study strongly supports the hypothesis that underuse of oral anticoagulants in high-risk patients importantly contributes to AF-associated stroke. CHA(2) DS(2) -VASc score appears to be a more valuable risk stratification tool than CHADS(2) score. Preventive measures should focus on optimizing pre-stroke detection of AF and better implementation of present AF-guidelines with respect to anticoagulation therapy.
© 2012 The Author(s) European Journal of Neurology © 2012 EFNS.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22788384     DOI: 10.1111/j.1468-1331.2012.03804.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  11 in total

Review 1.  Benefit-risk assessment of dabigatran in the treatment of stroke prevention in non-valvular atrial fibrillation.

Authors:  Sascha Meyer Dos Santos; Sebastian Harder
Journal:  Drug Saf       Date:  2014-05       Impact factor: 5.606

2.  Paroxysmal atrial fibrillation and the hazards of under-treatment.

Authors:  Konstantinos N Aronis; Jonathan L Thigpen; Yorghos Tripodis; Chrisly Dillon; Kristen Forster; Lori Henault; Emily Kate Quinn; Peter B Berger; Nita A Limdi; Elaine M Hylek
Journal:  Int J Cardiol       Date:  2015-09-11       Impact factor: 4.164

3.  [Patient selection for the implantation of a left atrial appendage occluder in primary and secondary prevention of cardioembolic stroke in atrial fibrillation].

Authors:  C W Israel; D Ridjab; W N Tschishow; J Buddecke
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2013-03

Review 4.  [Consensus statement: Management of oral anticoagulation for stroke prevention in patients with nonvalvular atrial fibrillation].

Authors:  Thomas Maria Helms; Sigmund Silber; Andreas Schäfer; Florian Masuhr; Frederick Palm; Harald Darius; Karsten Schrör; Dietmar Bänsch; Peter Bramlage; Johannes Hankowitz; Christoph A Karle; Tom Stargardt; Joachim Weil; Johann Christoph Geller
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2016-09

5.  Intracerebral haemorrhage in a population-based stroke registry (LuSSt): incidence, aetiology, functional outcome and mortality.

Authors:  F Palm; N Henschke; J Wolf; K Zimmer; A Safer; R J Schröder; G Inselmann; C Brenke; H Becher; A J Grau
Journal:  J Neurol       Date:  2013-06-28       Impact factor: 4.849

Review 6.  Risk Factor Management in Atrial Fibrillation.

Authors:  Axel Brandes; Marcelle D Smit; Bao Oanh Nguyen; Michiel Rienstra; Isabelle C Van Gelder
Journal:  Arrhythm Electrophysiol Rev       Date:  2018-06

7.  Baseline characteristics in stroke patients with atrial fibrillation: clinical trials versus clinical practice.

Authors:  Christian Tanislav; Sonja Milde; Sabine Schwartzkopff; Björn Misselwitz; Nicole Sieweke; Manfred Kaps
Journal:  BMC Res Notes       Date:  2015-06-25

8.  Under-prescribing of Prevention Drugs and Primary Prevention of Stroke and Transient Ischaemic Attack in UK General Practice: A Retrospective Analysis.

Authors:  Grace M Turner; Melanie Calvert; Max G Feltham; Ronan Ryan; David Fitzmaurice; K K Cheng; Tom Marshall
Journal:  PLoS Med       Date:  2016-11-15       Impact factor: 11.069

Review 9.  Atrial high-rate episodes and stroke prevention.

Authors:  A John Camm; Emmanuel Simantirakis; Andreas Goette; Gregory Y H Lip; Panos Vardas; Melanie Calvert; Gregory Chlouverakis; Hans-Christoph Diener; Paulus Kirchhof
Journal:  Europace       Date:  2017-02-01       Impact factor: 5.214

10.  Use of oral anticoagulation therapy in atrial fibrillation after stroke: results from a nationwide registry.

Authors:  Stine Funder Jespersen; Louisa M Christensen; Anders Christensen; Hanne Christensen
Journal:  Thrombosis       Date:  2013-11-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.